Drug Trial Radar · NCT07342881
Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Mar 10, 2026
Primary completion
Jul 29, 2026
Study completion Jul 29, 2026
Sponsor
- Lead sponsor
- Aligos TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for age, body weight and, to the extent possible, for sex.
Conditions
- Chronic Hepatitis B Infection
Interventions
Pevifoscorvir Sodium (ALG-000184)Drug
Pevifoscorvir Sodium (ALG-000184) Single oral doses of 100 mg pevifoscorvir sodium
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration time curve [AUC]Time frame: Up to 4 days
- Maximum plasma concentration [Cmax]Time frame: Up to 4 Days
- Minimum plasma concentration [Cmin]Time frame: Up to 4 Days
- C0 [predose]Time frame: Up to 4 days
- Half-life [t1/2]Time frame: Up to 4 Days
- Time to maximum plasma concentration [Tmax]Time frame: Up to 4 Days
- Apparent Clearance (CL/F)Time frame: Up to 4 Days
- Apparent Volume of Distribution (V/F)Time frame: Up to 4 Days
- Total Amount of Drug Excreted in Urine (Ae)Time frame: Up to 4 Days
- Renal Clearance (CLr)Time frame: Up to 4 Days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Orlando Clinical Research Center
Orlando, Florida
Genesis Clinical Trials
Tampa, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.